Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632358 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 279
- Enrollment target
NCT01632358 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 279 participants.
The verdict
NCT01632358, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 279 participants
- Enrollment target
Study Summary
The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
Interventions
- DRUG Placebo
- DRUG TAP311 capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632358
The ClinicalTrials.gov registry entry for NCT01632358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01632358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632358 about?
NCT01632358 is a clinical study titled "Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients". The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
What is the current status of trial NCT01632358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 279 participants. The study started on 2012-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01632358?
The interventions under investigation include: Placebo (DRUG), TAP311 capsules (DRUG).
Who is sponsoring clinical trial NCT01632358?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.